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Involvement of the central nervous system (CNS) in non-small cell lung cancer (NSCLC) patients is frequent and usually presents a diagnostic and therapeutic challenge. In a large 
cohort of NSCLC patients analyzed according to diagnosis-specific graded prognostic 
score, median survival from diagnosis of brain metastases was 7 months.1 Other series 
reported shorter survival, usually in the range of 3 to 6 months, depending on institutional 
profiles and patient selection criteria. Patients with CNS involvement typically present with 
headache, seizures, and a range of neurological deficits. Change in mental status, signs of 
depression, or psychosis may occasionally call for psychiatric assistance. Complications 
from CNS involvement are frequently devastating, leading to poor quality of life, and phys-
ical and emotional suffering. Patients with CNS involvement are typically excluded from 
clinical trials, and this severely limits our knowledge on their optimal management. This 
limitation is currently recognized by many national health authorities, and researchers are 
encouraged to include in clinical trials separate cohorts of patients with CNS involvement.
Careful clinical examination and magnetic resonance imaging most often results 
in appropriate diagnosis. Lumbar puncture and examination of cerebrospinal fluid (CSF) 
should be part of diagnostic work up in cases of suspected leptomeningeal carcinomatosis. 
Although increased risk of early brain dissemination has long been attributed to adenocarci-
noma histology, the molecular basis of this phenomenon is poorly understood. CNS involve-
ment may be more common in patients with ALK rearranged NSCLC. Approximately 35% 
of patients enrolled in the PROFILE 1007, a phase III second-line study comparing ALK 
inhibitor crizotinib to chemotherapy, presented with brain metastases at screening.2 The 
putative involvement of ALK in the CNS dissemination is not surprising, given its biologi-
cal role as a tyrosine kinase receptor involved in the brain development.3
In this issue of the Journal of Thoracic Oncology, Dr. Gainor and colleagues4 report 
on two series of uncommon forms of CNS involvement in patients with ALK-rearranged 
NSCLC: intramedullary spinal cord metastases (ISCM) and leptomeningeal carcinoma-
tosis (LC). Of note, most of these patients developed ISCM or LC while on therapy with 
crizotinib, often with continuous extracranial response. Thus, poor penetration of crizotinib 
to the brain (“pharmacokinetic relapse”) rather than cellular resistance is suspected as the 
mechanism of ALK inhibitor failure. Presented cases add to the current knowledge on 
limited activity of crizotinib in the CNS, most probably due its low penetration through the 
blood brain barrier.5 Although clinical presentations described by Dr. Gainor and colleagues 
are relatively uncommon, they should call for attention in ALK-positive NSCLC patients 
treated with crizotinib, now increasingly used worldwide. Therapeutic options in patients 
with “pharmacokinetic relapses” in the CNS include radiotherapy (be it conventionally 
fractionated or stereotactic), surgery in very selected patients, and systemic treatment: 
a continuation of crizotinib “beyond CNS progression”, chemotherapy, or experimental 
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agents such as second generation ALK inhibitors or hsp90 
inhibitors.
Due to often prolonged systemic benefit from ALK 
inhibition, local therapies appear to be particularly impor-
tant in this group of patients. Whole brain radiotherapy, if 
not administered previously, may additionally disrupt the 
blood brain barrier, potentially increasing CSF concentration 
of crizotinib, as exemplified by our own experience. One of 
our patients, who progressed in the brain during continued 
response in the chest, achieved a response after whole brain 
radiotherapy (WBRT), with successful re-exposure to crizo-
tinib given in the recommended dose of 250 mg twice daily, 
lasting for more than 2 years. Several other patients are cur-
rently managed with this approach. Another promising crizo-
tinib retreatment strategy, published in the case reports section 
of this issue of the Journal of Thoracic Oncology, includes 
administration of 500 mg of crizotinib once daily, with a pos-
sible advantage of its increased peak concentration leading to 
better penetration to the brain.6 Several novel ALK inhibitors 
(LDK378, CH5424802, AP26113, TSR-011) appear to better 
penetrate through the blood brain barrier, which will hope-
fully translate into fewer CNS relapses and continued suc-
cessful ALK inhibition in patients with isolated failures in the 
CNS while on crizotinib therapy.
The reports by Dr. Gainor and Dr. Peled emphasize 
the importance of a phenomenon of CNS as a sanctuary 
site in ALK positive NSCLC, and pose new questions to be 
addressed in this increasingly recognized group of patients. Is 
active surveillance by imaging useful to detect and treat CNS 
metastases before they become symptomatic, often leading 
to dramatic neurological sequelae? Is it safe to administer 
WBRT concomitantly with crizotinib? To what extent and for 
how long WBRT disrupts the blood brain barrier and what 
crizotinib concentrations are expected in the CSF after radio-
therapy with different crizotinib administration schedules? 
Will CNS remain a sanctuary site for new generation of ALK 
inhibitors?
With these questions in mind, authors of both papers 
should be congratulated for careful evaluation of their patients. 
Their work may stimulate further research which will trans-
late into prolonged symptom-free survival of ALK-rearranged 
lung cancer patients with CNS involvement.
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